David Sinclair· PhD
And so we're going to talk about NAD boosters. We're going to talk about Metformin, berberine rapamycin, spermidine resveratrol fisetin and quercetin, and probably a few others. But those were sort of the highlight points.
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And so we're going to talk about NAD boosters. We're going to talk about Metformin, berberine rapamycin, spermidine resveratrol fisetin and quercetin, and probably a few others. But those were sort of the highlight points.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.